Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis Report 2024

Key Takeaways

• Major companies involved in the post-traumatic stress disorder (PTSD) pipeline drugs market include Hoffmann-La Roche, Jazz Pharmaceuticals, and GlaxoSmithKline among others.
• Leading drugs currently under pipeline include Sertraline, Nabiximols, and Brexpiprazole among others.
• Regulatory authorities such as the United States FDA and EMA play an essential role in post-traumatic stress disorder (PTSD) treatment as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients having post-traumatic stress disorder (PTSD).

Report Coverage

The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing post-traumatic stress disorder (PTSD) clinical trials. It covers various aspects related to the details of each of these drugs under development for post-traumatic stress disorder (PTSD). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-traumatic stress disorder (PTSD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-traumatic stress disorder (PTSD). 

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing post-traumatic stress disorder (PTSD) pipeline development activities are covered. Moreover, post-traumatic stress disorder (PTSD) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Outlook

Post-traumatic stress disorder  (PTSD) is a mental health condition that develops after a traumatic event. The symptoms of this disorder involve anxiety, flashbacks, negative thoughts and beliefs, and hypervigilance among others. People who go through traumatic events may have temporary difficulty in adjusting and coping. Moreover, if the symptoms get worse and interfere with day-to-day functioning, it can develop into PTSD. The symptoms of PTSD may start within one month of a traumatic event. It can interfere with the ability to do normal daily tasks. Generally, post-traumatic stress disorder (PTSD) symptoms are grouped into four types, including, intrusive memories, negative changes in thinking and mood, avoidance, and changes in physical and emotional reactions. 

There are two types of post-traumatic stress disorder (PTSD) including acute stress disorder and complex PTSD (CPTSD). Acute stress disorder is a short-term mental health condition which can occur within the first month after experiencing a traumatic event. Complex PTSD is a mental health condition which can develop if a person experiences chronic trauma which includes long-term child physical or sexual abuse, long-term domestic violence and war among others.

The primary post-traumatic stress disorder (PTSD) treatment includes psychotherapy (talk therapy), especially forms of cognitive behavioral therapy (CBT). The specific forms of CBT include cognitive processing therapy, eye movement desensitization and reprocessing (EMDR) therapy, group therapy, prolonged exposure therapy and trauma-focused CBT. Currently, there are no medications approved by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). However, healthcare providers prescribe certain medications including antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) and anti-anxiety medications.

Several pharma companies are developing innovative treatments to manage post-traumatic stress disorder (PTSD). There has been a significant growth in the treatment options for the condition. Positive results from clinical trials during the past decade of medication-assisted psychotherapy are providing hope to manage the disease effectively. 

Post-Traumatic Stress Disorder (PTSD) – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of post-traumatic stress disorder (PTSD) drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

EMR’s post-traumatic stress disorder (PTSD) therapeutics assessment report covers 50+ drug analyses based on drug classes:

• Recombinant Fusion Proteins
• Small Molecule
• Monoclonal Antibody
• Peptide
• Polymer
• Gene Therapy

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Post-Traumatic Stress Disorder (PTSD) – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for post-traumatic stress disorder (PTSD) with 226 pipeline drugs in phase II.

Post-Traumatic Stress Disorder (PTSD) – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under post-traumatic stress disorder (PTSD) pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Currently under phase II, Jazz Pharmaceuticals is developing an investigational small molecule drug called JZP150 to treat post-traumatic stress disorder (PTSD) in adults. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-traumatic stress disorder (PTSD). 

Post-Traumatic Stress Disorder (PTSD) Clinical Trials Assessment – Competitive Dynamics

The EMR post-traumatic stress disorder (PTSD) drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in PTSD clinical trials:

• Hoffmann-La Roche
• Synchroneuron Inc.
• Klarisana Physician Services PLLC
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Apollo Neuroscience, Inc.
• Palo Alto Health Sciences, Inc.
• Jazz Pharmaceuticals
• HealthTech Connex Inc.
• Boehringer Ingelheim
• GlaxoSmithKline
• Nobilis Therapeutics Inc.
• Others

Post-Traumatic Stress Disorder (PTSD) – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for post-traumatic stress disorder (PTSD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of post-traumatic stress disorder (PTSD) drug candidates.

Drug: Balovaptan

The trial is designed to evaluate the safety and effectiveness of administering 10 mg of balovaptan orally once a day in comparison to a similar placebo in adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Hoffmann-La Roche and is currently under phase II.

Drug: JZP150

The objective of the study is to assess the clinical safety and effectiveness of ZP150 in the treatment of adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Jazz Pharmaceuticals and is currently under phase II.

Drug: BI 1358894

Boehringer Ingelheim is developing this drug and is currently under phase II. The study is being conducted to find out whether the drug improves symptoms in post-traumatic stress disorder (PTSD) affected patients.

Reasons To Buy This Report

The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for post-traumatic stress disorder (PTSD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into post-traumatic stress disorder (PTSD) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Post-Traumatic Stress Disorder (PTSD) – Pipeline Assessment Report

• Which companies/institutions are leading the post-traumatic stress disorder (PTSD) drug development?
• What is the efficacy and safety profile of post-traumatic stress disorder (PTSD) pipeline drugs?
• Which company is leading the post-traumatic stress disorder (PTSD) pipeline development activities?
• What is the current post-traumatic stress disorder (PTSD) commercial assessment?
• What are the opportunities and challenges present in the post-traumatic stress disorder (PTSD) drug pipeline landscape?
• What is the efficacy and safety profile of post-traumatic stress disorder (PTSD) pipeline drugs?
• Which company is conducting major trials for post-traumatic stress disorder (PTSD) drugs?
• Which companies/institutions are involved in post-traumatic stress disorder (PTSD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in post-traumatic stress disorder (PTSD)?

Related Reports

Post Traumatic Stress Disorder (PTSD) Market

Anxiety and Depression Treatment Market

Mental Health Treatment Market